이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Oligometastatic 비소 세포 폐암 환자에 대한 일차 면역 요법 기반 치료 기반 치료 기준 및 국소 절제 치료. (OliGRAIL)

2026년 11월 4일 업데이트: Gustave Roussy, Cancer Campus, Grand Paris

Oligometastatic 비소 세포 폐암 환자에 대한 1 차 면역 요법 기반 치료 기반 치료 표준 및 국소 절제 치료 : 무작위, 멀티 센터, 오픈 라벨 상 III 연구

First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study

연구 개요

연구 유형

중재적

등록 (추정된)

124

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Caen, 프랑스, 14076
      • Lille, 프랑스, 59000
        • 모병
        • Centre Oscar Lambret
        • 연락하다:
      • Lyon, 프랑스, 69000
        • 모병
        • Hospices Civils de Lyon (HCL)
        • 연락하다:
      • Nice, 프랑스, 06001
        • 모병
        • CHU Nice
        • 연락하다:
      • Nîmes, 프랑스, 30029
        • 모병
        • Institut de Cancérologie du Gard
        • 연락하다:
      • Paris, 프랑스, 75014
        • 모병
        • Hôpital Paris Saint- Joseph
        • 연락하다:
      • Tarbes, 프랑스, 65000
        • 모병
        • Polyclinique Ormeau
        • 연락하다:
    • Hauts-de-France
      • Creil, Hauts-de-France, 프랑스, 60100
        • 모병
        • Institut de Radiothérapie du Sud de l'Oise
        • 연락하다:
        • 수석 연구원:
          • Andres HUERTAS, MD
    • Provence-Alpes-Côte d'Azur Region
      • Avignon, Provence-Alpes-Côte d'Azur Region, 프랑스, 84000
        • 모병
        • Centre Sainte-Catherine
        • 연락하다:
        • 수석 연구원:
          • Nicolas POUREL, MD
    • Île-de-France Region
      • Saint-Cloud, Île-de-France Region, 프랑스, 92210
        • 모병
        • Institut Curie
        • 연락하다:
      • Villejuif, Île-de-France Region, 프랑스, 94805
        • 모병
        • Gustave Roussy
        • 수석 연구원:
          • Antonin LÉVY, MD
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Histologically proven advanced synchronous oligometastatic stage IV NSCLC.
  • NSCLC patients eligible first line immunotherapy-based SoC according to the European Marketing Authorization.
  • PDL1 status available.
  • Metastases eligible to RLT according to the local multidisciplinary board (MTB): ≤5cm each in CT scan, excluding primary tumour.
  • Maximum 5 metastases in 3 organs (EORTC criteria), according to brain MRI and FDG-PET.
  • Symptomatic lesions requiring urgent palliative radiation, is permitted prior to randomization. These treated lesions should be counted towards the total number of metastases at the time of enrolment.
  • Clinically required brain metastases (BM) ablation (surgery and/or SBRT) is permitted and BM count within the total number of 5 lesions. The patient would then be randomized to treatment of their extracranial disease.
  • Acceptable organ function for RLT.
  • ECOG performance status (PS) 0-1.
  • Measurable lesions according to RECIST V1.1 on standard imaging.
  • Patient aged 18 or more.
  • Woman of childbearing potential must agree to use adequate contraception (implant type, vaginal ring, contraceptive pill, contraceptive patch, Intrauterine Device (IUD), etc.) for the duration of study participation and up to 6 months after completing treatment/therapy, in addition, male partners use a condom during this same period. Male patients must agree to use condom for the duration of study participation and up to 6 months after completing treatment/therapy.
  • Patients affiliated to the social security system.
  • Patient should understand, sign, and date the informed consent form written in French prior to any protocol-specific procedures performed.
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits, and examinations including follow-up.

Exclusion Criteria:

  • Non-squamous NSCLC with targetable tumour mutations and approved first line targeted therapy (such as EGFR, ALK and ROS1).
  • Metastases not eligible to RLT: e.g. brainstem or diffuse serosal metastases (meningeal, pericardial, pleural, peritoneal, mesenteric) or that invades the gastrointestinal tract.
  • Brain metastases only, without extra-cerebral metastases.
  • Uncontrolled severe comorbidity, symptomatic interstitial lung disease or active infection.
  • Prior therapy with T-cell costimulation or immune checkpoint-targeted agents within 1 year.
  • Uncontrolled concomitant (<1-year) malignancy except adequately treated basal or squamous cell carcinoma of the skin, or in-situ carcinoma of any organ or in-situ melanoma of the skin.
  • Persons deprived of liberty by judicial or administrative decision.
  • Persons subject to a legal protection measure (guardianship, curatorship, safeguard of justice).
  • Persons not affiliated to a social security system or equivalent.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Experimental arm: RLT + SoC-based immunotherapy (+/- chemotherapy)

RLT of all metastatic sites should be administered within 3 months after randomization and should not delay SoC-based immunotherapy administration.

RLT of all metastatic sites. The possible RLT options will be SBRT, interventional radiology and/or minimally invasive surgery. Depending on the metastatic site, access and patient condition, the best RLT should be initially discussed in a case-to-case basis at the local multidisciplinary board (MTB).

The primary tumour and initially invaded lymph nodes should be treated during the maintenance phase. Curative-intent approach modalities (e.g. hypofractionated intensity-modulated thoracic radiation therapy or surgery) should be discussed at the local MTB.

다른 이름들:
  • SBRT
  • 중재방사선
  • 최소 침습 수술

Current French SoC will be used. Main SoC-based immunotherapy includes:

  • Platinum-based chemotherapy combined with an anti PD-1 immunotherapy (pembrolizumab). Pemetrexed-platinum combinations may be used in non- squamous carcinoma, while paclitaxel-platinum combination is favoured in squamous carcinoma.
  • Anti PD-1 monotherapy if PD-L1 ≥ 50% is a possible alternative (pembrolizumab or atezolizumab or cemiplimab).

Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association. Bevacizumab is not allowed given possible interactions with RLT.

Maintenance/Immunotherapy alone will be pursued at the investigator's discretion according to the standard procedures (toxicity, progression, choice of the patient...).

활성 비교기: Control arm: SoC-based immunotherapy (+/- chemotherapy)

SoC-based immunotherapy (+/- chemotherapy) will be administered every 3 weeks

Current French SoC will be used. Main SoC-based immunotherapy includes:

  • Platinum-based chemotherapy combined with an anti PD-1 immunotherapy (pembrolizumab). Pemetrexed-platinum combinations may be used in non- squamous carcinoma, while paclitaxel-platinum combination is favoured in squamous carcinoma.
  • Anti PD-1 monotherapy if PD-L1 ≥ 50% is a possible alternative (pembrolizumab or atezolizumab or cemiplimab).

Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association. Bevacizumab is not allowed given possible interactions with RLT.

Maintenance/Immunotherapy alone will be pursued at the investigator's discretion according to the standard procedures (toxicity, progression, choice of the patient...).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall Survival (OS).
기간: From date of randomization up to two years after the randomization of the last patient or documented death.

Time from randomization to the date of documented death from any cause or last follow-up.

From date of randomization up to two years after the randomization of the last patient or documented death.

2차 결과 측정

결과 측정
측정값 설명
기간
Progression-free survival (PFS) according to RECIST 1.1.
기간: From date of randomization up to two years after the randomization of the last patient or documented death.

Time between the randomization date and the date of observation of a progression of the disease according to RECIST 1.1 or death of the patient (all causes combined) or date of last follow-up if the patient is alive without progression or lost to follow up.

From date of randomization up to two years after the randomization of the last patient or documented death.
immune Progression-free survival (iPFS) according to iRECIST.
기간: From date of randomization up to two years after the randomization of the last patient or documented death.

Time between the randomization date and the date of observation of an progression of the disease according to iRECIST 1.1 or death of the patient (all causes combined) or date of last follow-up if the patient is alive without progression or lost to follow up.

From date of randomization up to two years after the randomization of the last patient or documented death.
Number of side effects measured by CTCAE V.5.
기간: From date of randomization up to two years after the randomization of the last patient or documented death.

Acute/ late adverse events graded by CTCAE v5 (toxic death and serious adverse events) and their imputability to treatment.

From date of randomization up to two years after the randomization of the last patient or documented death.
EORTC Quality of Life Questionnaire-C30 (EORTC QLQ-C30).
기간: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

The EORTC Quality of Life Questionnaire-C30 (EORTC QLQ-C30) contains 30 questions and assesses the quality of life of oncological patients multidimensionally over 10 subscales. All sub-scales and the 6 individual items have a score range from 0 to 100 points. A higher score represents better function and a higher quality of life. In the symptom subscale, however, a higher score represents a higher level of symptoms or problems.

From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
EORTC Quality of Life Questionnaire Lung Cancer-specific-13 (QLQ-LC-13).
기간: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

EORTC Quality of Life Questionnaire Lung Cancer-specific-13 (QLQ-LC-13) is a specific companion module used in conjunction with the EORTC QLQ-C30 and specifically developed for patients with Lung Cancer, and reliable in LC specific Qol assessment. The EORTC QLQ-LC13 comprises 13 item that measure lung cancer-related symptoms. Each items use the same 1-to-4 verbal response scale as the QLQ-C30 items, and domain scores are also transformed to a 0-to-100 metric. A higher score represents better function and a higher quality of life.

From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
EuroQol-5D-5L Questionnaire (EQ-5D-5L).
기간: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

The EuroQol-5D-5L Questionnaire (EQ-5D-5L) descriptive system of 5 health dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Index scores range from -0.59 to 1; 1 is the best possible health state. Negative values represent health states perceived as worse than dead, which is equal to 0. Used alongside the EQ-5D, the EQ visual analog scale (VAS) is a 20 cm VAS "assessing your own health today" with endpoints labeled "Best imaginable health state" (100) and "Worst imaginable health state" (0).

From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
Clearance of circulating tumour DNA (ctDNA).
기간: At the randomization, then Week 6 and Month 4 after randomization.

ctDNA assessed in plasma.

At the randomization, then Week 6 and Month 4 after randomization.
Economic evaluation.
기간: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

Incremental cost per Quality-adjusted life year (QALY based on EQ-5D-5L measures), incremental net monetary benefit. Assess the cost-utility (cost per QALY) of RLT + immunotherapy-based SoC compared to immunotherapy-based SoC alone.

From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 9월 9일

기본 완료 (추정된)

2030년 2월 1일

연구 완료 (추정된)

2030년 2월 1일

연구 등록 날짜

최초 제출

2025년 1월 16일

QC 기준을 충족하는 최초 제출

2025년 2월 18일

처음 게시됨 (실제)

2025년 2월 21일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2023-503326-39-00
  • 2023/3729 (기타 식별자: CSET number (Gustave Roussy ID))
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다